Assessing the beneficial effect of Lactobacillus plantarum MS1 and Lactobacillus delbrueckii YN1 on colitis in a rat model.

BACKGROUND AND

OBJECTIVES

Probiotics are effective in improving inflammatory bowel disease (IBD). This study assessed the effect of mesalazine and two candidate probiotics on the improvement of acetic acid (AA)-induced colitis model.

MATERIALS AND

METHODS

Lactobacillus plantarum MS1and Lactobacillus delbrueckii YN1 were used for IBD model in rat. Twenty-five male Wistar rats weighing 250 ± 50 grams were used in 5 classified groups: Control (CO); Colitis (CL); Colitis, Probiotic (CLP); Colitis, Mesalazine (CLM); Colitis, Probiotic, Mesalazine (CLPM) and the treatment period was 3 weeks. The rats were treated with mesalazine 30 mg/kg and probiotic 109 CFU/ml after induction of colitis. Histopathological and immunological analyses were performed to evaluate the effects of probiotic bacteria on IBD.

RESULTS

The results showed that the probiotic bacteria reduced inflammation (P<0.05), extent (P<0.01), crypt abscesses (P<0.01), edema (P<0.05), inflammatory cell infiltration (P<0.5), and increased mucosa (P<0.001) in rats. Mesalazine administration in animals with colitis did not have a significant effect. Administration of probiotics in both CLP and CLPM groups reduced extent, crypt abscesses, edema, and inflammatory cell infiltration and showed an important role in the down-regulation of consolidation of pro-inflammatory factors (TNFα, IL-6, and IL-17), as well as up-regulation of anti-inflammatory factors such as IL-10.

CONCLUSION

Lactobacillus plantarum MS1 and Lactobacillus delbrueckii YN1 have shown significant potential in alleviating AA-induced colitis symptoms. Their administration leads to a marked reduction in pro-inflammatory cytokines such as TNF-α, IL-17, and IL-6, while enhancing IL-10 levels, indicating their promise as therapeutic candidates for inflammatory bowel disease (IBD).